Literature DB >> 34668103

Fixation stability improvement after occlusion treatment for severe amblyopia.

Shu Wang1,2,3,4,5, Leilei Zou1, Tian Tian2,3,4,5, Aiqin Zhan6, Yan Liu2,3,4,5, Wen Wen7,8,9,10, Hong Liu11,12,13,14,15.   

Abstract

BACKGROUND: To investigate the improvement of fixation stability of severe amblyopia with traditional patching treatment by the MP-1 microperimeter.
METHODS: Eighteen patients with severe unilateral amblyopia were enrolled and received prescribed 6 h per day of patching of the fellow eye with optical correction if needed. Fixation test was performed on eighteen severe unilateral amblyopia patients by the MP-1 microperimeter in baseline, 3-month and 6-month after treatment. The bivariate contour ellipse area (BCEA, deg2) was used to quantify fixation stability.
RESULTS: The RMANOVA showed that significant differences were found in best-corrected visual acuity (BCVA) between amblyopia eyes/fellow eyes (AE/FE) group (F = 113.52, p < 0.001) and among follow-up time (F = 74.684, p < 0.001). Moreover, a significant interaction could be found between AE/FE group and follow-up time (baseline/3-month/6-month, F = 60.189, p < 0.001). Post hoc analysis by Bonferroni showed significant improvement of BCVA in AE at 3-month (p < 0.001) and 6-month (p < 0.001), compared to baseline, and also significant between 3-month and 6-month (p = 0.002). The RMANOVA showed that significant differences were found in BCEA between AE/FE group (F = 8.432, p = 0.006) and among follow-up time (F = 10.431, p = 0.003). Moreover, a significant interaction could be found between AE/FE group and follow-up time (F = 9.099, p = 0.005). The mean BCEA of AE changed from 13.14 ± 17.97 deg2 at baseline to 6.03 ± 7.27 deg2 at 3-month (p = 0.084) and 3.38 ± 6.40 deg2 at 6-month (p = 0.018). No significant difference of BCEA in fellow eyes was found during the follow-up period (between baseline and 3-month: p = 0.230; between baseline and 6-month: p = 0.692. 0.89 ± 1.02, 0.58 ± 0.40, and 0.03 ± 0.04 deg2 for baseline, 3-month and 6-month, respectively). No significant correlation could be found between BCEA and BCVA of AE, both in enrollment and follow-up (p > 0.05).
CONCLUSIONS: The fixation stability in the amblyopic eyes is significantly worse than that of the fellow eyes in patients with unilateral severe amblyopia. The fixation stability became better after 6-month occlusion treatment, but the change of fixation stability was not correlated with visual acuity improvement. These quantitative results highlight the importance of fixation in the mechanism of amblyopia.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Amblyopia; Eccentric fixation; Fixation location; Fixation stability; MP-1 microperimeter

Mesh:

Year:  2021        PMID: 34668103     DOI: 10.1007/s10792-021-02084-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  5 in total

1.  Fixation patterns evaluation by means of MP-1 microperimeter in microstrabismic children treated for unilateral amblyopia.

Authors:  P Carpineto; M Ciancaglini; M Nubile; G Di Marzio; L Toto; L Di Antonio; L Mastropasqua
Journal:  Eur J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 2.597

2.  The use of the scanning laser ophthalmoscope in the evaluation of amblyopia (an American Ophthalmological Society thesis).

Authors:  David A Johnson
Journal:  Trans Am Ophthalmol Soc       Date:  2006

3.  A quantitative study of fixation stability in amblyopia.

Authors:  Vidhya Subramanian; Reed M Jost; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-19       Impact factor: 4.799

4.  Fixation stability measurement using the MP1 microperimeter.

Authors:  Michael D Crossland; Hannah M P Dunbar; Gary S Rubin
Journal:  Retina       Date:  2009-05       Impact factor: 4.256

5.  Abnormal Fixational Eye Movements in Amblyopia.

Authors:  Aasef G Shaikh; Jorge Otero-Millan; Priyanka Kumar; Fatema F Ghasia
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.